Apr 05, 2017
On Tuesday, Verona Pharma PLC stated that it has successfully enrolled and drugged a dose to the first patient in a clinical trial evaluating its under-trial drug RPL554 in its phase II study of treating cystic fibrosis.
Individually, the company stated that it will establish a primary public offering of its American Depositary Shares (ADS) on the NASDAQ. The total number of ADS’s to be given and the range of costing for the same has not yet been decided.
The most important objective of the placebo-governed single dosage trial, Phase II is to access the pharmacodynamics and pharmacokinetic profile and tolerability of RPL554 in up to 10 patients with Cystic Fibrosis, plus inspect the effect the drug has on the functions of the lung.
The clinical trial is being executed at the Cambridge Centre for Medical Research at Papworth Hospital, Cambridge, UK, which is believed to be one of the most prevalent dedicated cardiothoracic hospitals in Europe, by leading investigator Professor Andres Floto.
RPL554 is a one of a kind, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3/PDE4) along with anti-inflammatory in addition to bronchodilatory properties, presently under development for treating cystic fibrosis and chronic obstructive pulmonary disease (COPD).
Verona Pharma’s Chief Executive Officer Jan-Anders Karlsson said in a statement that, "RPL554 has a differentiated mechanism of action and pre-clinical data in cystic fibrosis combined with our positive clinical data in COPD leads us to believe it has the potential to be an important new treatment for this debilitating condition. We look forward to progressing the drug through this study and expect to announce top-line data in the first half of 2018,"
Former trials of the dual inhibitor drug in COPD patients have resulted that RPL554 could incur statistically considerable enhancements in lung function in comparison with placebo and many other clinically significant improvements in lung function when added to two regularly used bronchodilators as opposed to just one bronchodilator dispensed as a solo agent.
Karlsson also cited that the two latest therapies which have been approved for the condition are hinted just for a division of CF patients, and there is a demand for new, efficient, anti-inflammatory medications for treating the fundamental inflammation in cystic fibrosis.
Head of Research of the UK Cystic Fibrosis Trust, Paula Sommer says that the RPL554 clinical trial has the prospective to make a significant change to the cystic fibrosis patients and the team is quite pleased that the drug is approaching into this vital trial stage.
On Tuesday, shares in Verona Pharma were escalated by 4.3% at 145.49 pence.
Apr 11, 2017
All Copyrights reserve worldhealthcarenews.biz 2017.